68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Helena Lanzafame; Ilektra A. Mavroeidi; Kim M. Pabst; Mélanie Desaulniers; Marc Ingenwerth; Nader Hirmas; Lukas Kessler; Michael Nader; Timo Bartel; Stephan Leyser; Francesco Barbato; Martin Schuler; Sebastian Bauer; Jens T. Siveke; Ken Herrmann; Rainer Hamacher; Wolfgang P. Fendler

doi:10.2967/jnumed.123.267248

Research ArticleClinical Investigation

⁶⁸Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher and Wolfgang P. Fendler

Journal of Nuclear Medicine June 2024, 65 (6) 880-887; DOI: https://doi.org/10.2967/jnumed.123.267248

Helena Lanzafame

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ilektra A. Mavroeidi

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kim M. Pabst

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mélanie Desaulniers

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

4Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Marc Ingenwerth

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;

5Institute of Pathology, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nader Hirmas

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lukas Kessler

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

6Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Nader

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Timo Bartel

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stephan Leyser

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Francesco Barbato

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Martin Schuler

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sebastian Bauer

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;

7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jens T. Siveke

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

7National Center for Tumor Diseases West, Campus Essen, Essen, Germany; and

8Bridge Institute of Experimental Tumor Therapy and Division of Solid Tumor Translational Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ken Herrmann

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

6Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rainer Hamacher

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

3Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Wolfgang P. Fendler

1Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany;

2Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 6

June 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

⁶⁸Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Journal of Nuclear Medicine Jun 2024, 65 (6) 880-887; DOI: 10.2967/jnumed.123.267248

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

⁶⁸Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Journal of Nuclear Medicine Jun 2024, 65 (6) 880-887; DOI: 10.2967/jnumed.123.267248

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET

Google Scholar

Keywords

68Ga-FAPI PET
sarcoma
fibroblast activation protein
theranostic
cancer imaging

Main menu

User menu

Search

⁶⁸Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords